IMMUNeOCT: OCT LAR in the Induction of Immunologic Response in Patients with Neuroendocrine Neoplasms (NENs): A Perspective Observational and Translational Study (EudraCT2017-001613-83) Abstract #2801

Introduction: The possible impact of octreotide (OCT) Long-Acting Release (LAR) on the immune system regulation is largely unexplored.
Aim(s): With this intent, T-regolatory (Tregs) and Myeloid derived suppressor cells (MDSC) were evaluated in the peripheral blood of NEN patients (pts) during the treatment with OCT.
Materials and methods: Study of immune-regulatory cells was conducted by flowcytometry in 35 pts (29 GEP/NET/6 Lung/NET) evaluated at T0, at 2 weeks (T2w), 1 month (T1M), 3 (T3M) and 6 (T6M) after therapy.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD Alessandro Ottaiano

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2047 IMMUNeOCT Study: The Role of Octreotide LAR in Modulating the Immune Response in Patient with Neuroendocrine Tumors. EudraCT Number 2017-001613-83
Introduction: SSAs are used in the treatment of G1/G2 Neuroendocrine Neoplasms (NEN) in order to control symptoms and induce tumor shrinkage with an excellent tolerability profile. The role of immune response is crucial in defining the clinical response to treatment through the active stimulation of effector cells (T and NK cells) but also through the inhibition of tumor-induced immune suppression. The immune regulatory cells CD4-CD25-expressing Tregs and myeloid cellsMDSC can contribute to disease progression through various mechanisms.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD Salvatore Tafuto
#2930 Treatment of the Pinealoma: Experience from a Rare Case
Introduction: Pinealoma is an extremely rare type of neuroendocrine tumor without evidence-based systemic therapy.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Professor Jie Chen
Authors: Zhang Y, Liu M, Chen L, Guo Y, ...
#2684 Tumour-Infiltrating Neutrophils Predict Poor Survival of Non-Functional Pancreatic Neuroendocrine Tumour Patients after Curative Resection
Introduction: Non-functional pancreatic neuroendocrine tumours (NF-PanNETs) are steadily increasing in prevalence and present several clinical challenges.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr Wuhu Zhang
Authors: Zhang W, Wang W, ...
#2695 Different Treatment Options for Patients with Advanced Gastrointestinal Neuroendocrine Tumors
Introduction: Low sensitivity to chemotherapy leaves open question of optimal approach to drug therapy of neuroendocrine tumors (NETs). Somatostatin analogues (SSA) (octreotide, lanreotide) and mTOR inhibitors are successfully used in treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Alina Isiangulova
Authors: Isiangulova A, Khasanov R, ...
#3017 Patient and Healthcare Practitioner Perspectives of Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review
Introduction: Somatostatin analogs (SSAs) are used to treat acromegaly and neuroendocrine tumors (NETs). Two first-generation SSAs, octreotide and lanreotide, are available to patients (pts).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Costello Medical
Authors: Feuilly M, Jenni E, Cella D, ...